Merck halts blood cancer drug trials after risks outweigh benefits
8 sourcesUpdated Nov 18, 20261 min read

Sponsored
Merck & Co. has ended development of nemtabrutinib and discontinued its three phase 3 Bellwave trials for chronic lymphocytic leukemia and small lymphocytic lymphoma. The decision followed an independent monitoring committee’s review of Bellwave-011, which indicated the drug’s risks might outweigh its benefits; Merck confirmed that assessment before stopping the remaining studies. The move closes a program acquired with ArQule for $2.7 billion in 2019, after years of delays and reduced expectations for the drug.
Sponsored



